| Name | Title | Contact Details |
|---|
Ascend Medical is a membership healthcare platform that provides patients with 24/7 provider access through end-to-end technology and convenient mobile visits that come to your home, work, or anywhere around town.
The Counseling Service of Addison County (CSAC) is a local community mental health center located in Middlebury, Vermont. Since 1959, CSAC has been an integral part of the Addison County community. The Counseling Service offers a wide range of professional mental health and developmental services designed to meet the needs of those seeking help. We are able to provide a multi-disciplinary approach that draws on the expertise of our staff, which includes persons trained in developmental services, substance abuse treatment, psychiatry, psychology, mental health counseling, social work, family therapy, and child therapy. Our goal is to help people live more productive lives in their communities. The following Mission Statement and Values were adopted by the CSAC Board of Directors at their October 9th, 1997 Board meeting. The Mission Statement and Values are the result of several staff and community meetings, where input was gathered. The Counseling Service of Addison County is committed to promoting stable and safe communities by helping people live emotionally healthy and satisfying lives. We strive to provide the best mental health, substance abuse, and developmental services to improve the quality of life for all community members. We work collaboratively with community organizations to help individuals and families achieve maximum wellness.
SynGen advances regenerative medicine and other emerging applications for high-value cells by providing researchers, clinicians and manufacturers with innovative, robust systems that improve the recovery, purity and viability of stem and other clinically important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture.
Protech Home Medical is a rapidly growing leader in the provision of clinical respiratory equipment and service to patients.
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.